We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Stem Cells Not Progenitors Can Trigger Skin Cancer Growth

By LabMedica International staff writers
Posted on 21 Jul 2016
Cancer researchers have discovered that stem cells can initiate development of malignant skin tumors, while progenitor cells are limited to triggering only benign growths.

A progenitor cell is similar to a stem cell, in that it has a tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and is pushed to differentiate into its "target" cell. More...
The most important difference between stem cells and progenitor cells is that stem cells can replicate indefinitely, whereas progenitor cells can divide only a limited number of times.

Investigators at the Université Libre de Bruxelles (Belgium) and the University of Cambridge (United Kingdom) sought to identify the type of cells that initiated formation of basal cell carcinoma, the most common form of skin cancer. To this end they assessed the impact of oncogenic hedgehog signaling in distinct cell populations and their capacity to induce cancer growth.

They reported in the July 8, 2016, online edition of the journal Nature that in a transgenic mouse model system only stem cells, and not progenitors, were competent to initiate tumor formation upon oncogenic hedgehog signaling. Clones derived from stem cells were able to overcome apoptosis and continue to divide and proliferate unchecked, developing into basal cell carcinoma. In contrast, the growth of clones derived from progenitor cells was checked by increasing levels of apoptosis, leading to the formation of benign lesions.

"It is incredibly rare to identify a cancer cell of origin and until now no one has been able to track what happens on an individual level to these cells as they mutate and proliferate," said senior author Dr. Cédric Blanpain, a professor at the Université Libre de Bruxelles. "We now know that stem cells are the culprits: when an oncogene in a stem cell becomes active, it triggers a chain reaction of cell division and proliferation that overcomes the cell's safety mechanisms."

"While this has solved a long-standing scientific argument about which cell types can lead to invasive skin tumors, it is far more than just a piece of esoteric knowledge," said contributing author Dr. Benjamin Simons, professor of physics at the University of Cambridge. "It suggests to us that targeting the pathways used in regulating cell fate decisions - how stem cells choose between cell proliferation and differentiation - could be a more effective way of halting tumors in their tracks and lead to potential new therapies."

Related Links:
Université Libre de Bruxelles
University of Cambridge

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.